Essential tremor
Drug research and approvals for essential tremor: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 60 studies of essential tremor are recruiting on ClinicalTrials.gov, and Health Canada has authorized 7 drug trials for it since 2013.
- Recruiting worldwide: 60
- Trials authorized in Canada: 7
- FDA orphan approvals: 0
- EU medicines: 0
- The Encora X1™ in a Real World Observational StudyNCT07911488 · Not reported · Encora, Inc. · starts Nov 1, 2026
- Intraoperative Microelectrode Recordings Using MAVEN Compared to Standard Recording ApparatusesNCT07868614 · Not reported · Mayo Clinic · starts Jul 29, 2025
- Effects of Microelectrode-based Brain Stimulation in HumansNCT07820189 · Not applicable · Lund University · starts Oct 15, 2026
- Wearable for Assessing Tremor and Continuous Health in Parkinson's Disease and Essential TremorNCT07787299 · Not reported · Heriot-Watt University · starts Nov 1, 2026
- Non-Invasive Neuromodulation for Essential Tremor: Long-Term Safety and Effectiveness StudyNCT07774598 · Not applicable · Ruijin Hospital · starts Dec 15, 2025
- Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb…NCT07673107 · Phase 2 · AbbVie · starts Jun 23, 2026
- Open Label Study for the Use of Low Intensity Focused Ultrasound for Essential TremorNCT07599592 · Early Phase 1 · University of California, Los Angeles · starts May 1, 2026
- Closed-loop TMS for TremorNCT07574164 · Not applicable · University of Oxford · starts Jan 1, 2024
- Investigating Subcortical Contributions to Speech Sequencing in Deep Brain Stimulator RecipientsNCT07455760 · Not applicable · Boston University Charles River Campus · starts Feb 18, 2026
Phase 3 2
- TopiramateCarbonic anhydrase II inhibitor
- PramipexoleD2-like dopamine receptor agonist
Phase 2 12 of 17
- Octanol
- IncobotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- SuvecaltamideVoltage-gated T-type calcium channel modulator
- T-2000
- OxybateGABA-B receptor agonist
- BrexanoloneGABA-A receptor; anion channel positive allosteric modulator
- ZuranoloneGABA-A receptor; anion channel positive allosteric modulator
- MethazolamideCarbonic anhydrase VII inhibitor
- PerampanelGlutamate receptor ionotropic AMPA antagonist
- AcamprosateGlutamate [NMDA] receptor antagonist
- ZonisamideSodium channel alpha subunit blocker
Phase 1 or earlier 6
- Octanoic acid
- LevetiracetamSynaptic vesicle glycoprotein 2A modulator
- DronabinolCannabinoid CB1 receptor agonist
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
- Ulixacaltamide
- PregabalinVoltage-gated calcium channel modulator
How its trials ended
223 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 36 whose ending is known, 28% met their primary endpoint, 6% missed it and 67% stopped early.
- Completed, result not reported9944%
- Ongoing5926%
- Status unknown2913%
- Stopped: other or unclear146%
- Met its primary endpoint104%
- Stopped: enrollment or feasibility63%
- Stopped: sponsor or business decision42%
- Missed its primary endpoint21%
| Jun 18, 2026 | A phase 2b multicenter, randomized, double-blind, placebo-controlled study with an open-label period to evaluate the efficacy and safety of agn 151607 dp…AGN-151607-DP (gemibotulinumtoxina) | AbbVie | Ongoing |
| Nov 5, 2021 | A phase 2 multicenter, randomized, double-blind, placebo-controlled study of botox® (botulinum toxin type a) purified neurotoxin complex for the treatment of…Botox | AbbVie | Closed |
| Oct 19, 2021 | A phase 2, randomized, double-blind, placebo-controlled, dose range finding clinical trial to evaluate the tolerability, safety, and efficacy of PRAX-944 in…PRAX-944 | Praxis Precision Medicine | Ongoing |
| Mar 17, 2021 | A phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and pharmacokinetics of ES-481 in adult patients with essential…ES-481 | Es Therapeutics, Inc. | Closed |
| Sep 28, 2018 | Assessment of safety and feasibility of exablate neuro system to perform auto-focusing echo imaging in patients with idiopathic essential tremor with…Perflutren | Insightec | Pending |
| Jun 26, 2015 | Use of kinematic assessment of hand tremor pre- and post-treatment with botulinum toxin type a in essential tremor and Parkinson diseaseXeomin | Lawson Health Research Institute | Ongoing |
| Jan 15, 2015 | Botulinum toxin type a for injection of bilateral upper extremity tremor in patients with essential tremor using kinematic assessmentXeomin (incobotulinumtoxina) | Lawson Health Research Institute | Pending |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA